Please login to the form below

Not currently logged in

Patheon hires Covance's Michael Lehmann for global pharma role

He joins the contract development and manufacturing company as president of global pharmaceutical development services

Michael Lehmann has left contract research organisation Covance to join Patheon as president of global pharmaceutical development services.

Patheon, which provides both contract development and manufacturing services to pharma companies, said that Lehmann's appointment will help drive the company's growth as it continues to transform its business amid varying marketing conditions.

This includes the company's recent acquisition of speciality pharma firm Banner Pharmacaps for $255m.

"I am pleased to be welcoming Mike and getting him quickly integrated with Patheon's leadership team," stated James Mullen, Patheon's CEO.

"He is a highly accomplished senior executive with a proven track record in the healthcare, life sciences and drug development sectors.”

Lehmann's most recent role was corporate senior VP and general manager of the global early development business of the contract research organisation (CRO) Covance.

During his time in this role, he helped Covance secure deals with both Lilly and Sanofi.

Prior to joining Covance, Lehmann spent 17 years at GE Healthcare in several senior roles, including general manager of multivendor services.

2nd November 2012

From: Research, Sales



Featured jobs

Subscribe to our email news alerts


Add my company

Transforming healthcare through effective collaboration. Making work to feel proud of.

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...